docetaxel

CDH13 is highly expressed in HCC and may promote angiogenesis, immune evasion, and metabolic reprogramming via the FOXA1-CDH13 axis, suggesting its potential as a therapeutic target.

P1/2, N=314, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed

P1, N=15, Active, not recruiting, South Metropolitan Health Service | Recruiting --> Active, not recruiting

Our findings underscore the prognostic value of the identified genes and the immunosuppressive TME in TP53-mutant breast cancer. The identification of drug candidates with strong binding affinities to key proteins provides promising avenues for targeted therapy in this high-risk patient population.

P1/2, N=649, Recruiting, Amgen | Trial completion date: Nov 2028 --> Jun 2028 | Trial primary completion date: Dec 2026 --> Jul 2026

P3, N=790, Completed, ECOG-ACRIN Cancer Research Group | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Jan 2025

We integrate data on epidermal growth factor receptor inhibitors, phosphoinositide-3-kinase inhibitors, taxanes such as docetaxel, fluoropyrimidines such as capecitabine, immune checkpoint inhibitors, BRAF and MEK inhibitors, mechanistic target of rapamycin inhibitors, Bruton tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy. We highlight the vulnerability of older adults, in whom age-related skin changes, comorbidities and polypharmacy amplify the impact of these events while evidence from dedicated prospective studies remains scarce. The review synthesizes practical, mechanism-oriented strategies for prevention and stepwise management, from basic skin care and photoprotection to targeted use of antibiotics, corticosteroids and treatment modification, with the goal of supporting timely recognition of cutaneous toxicity and multidisciplinary care that preserves both quality of life and the anticancer efficacy of therapy.

This study demonstrated that synthetic eugenol derivatives potentiated the effects of docetaxel in prostate cancer cells. Further research is necessary to elucidate the underlying mechanisms and to better understand its clinical advantages in prostate cancer therapy.

According to the European Society for Medical Oncology guidelines for non-oncogene-addicted metastatic non-small-cell lung cancer (NSCLC), patients with metastatic squamous-cell carcinoma (LUSC) or metastatic non-squamous NSCLC with performance status 2 and PD-L1 < 50% may receive single-agent chemotherapy with gemcitabine (GEM), docetaxel (DOC), or vinorelbine. Analysis of three key long non-coding RNAs (lncRNAs)-MALAT1, NEAT1, and HOTAIR-showed variable expression in the studied cell lines as a potential response to DOC and GEM treatment. Our findings indicate different cellular effects of GEM and DOC in NSCLC cell lines and provide an overview of how currently used chemotherapeutics may influence the expression of lncRNAs.

P1, N=168, Completed, AbbVie | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025

P3, N=800, Not yet recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2029

P1, N=159, Not yet recruiting, InSilico Medicine Hong Kong Limited | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Dec 2028 --> Jun 2029